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1. Introduction 
1.1 Definition 
Kawasaki disease to was described in 1967 by Tomisu Kawasaki (Kawasaki,  1967). it is 
manifested by an acute-course febrile syndrome associated with small-to-medium vessel 
vasculitis, which can lead to severe cardiovascular complications, including myocarditis, 
pericardial effusion, valve injuries, coronary aneurisms, and myocardial infarction, 
eventually involving many organs.  
1.2 Epidemiology 
Kawasaki disease (KD) is not well known worldwide; in Japan, in a recent survey 
(Nakamura, 2008), an increase was found of ( 151.0 to 184.0/100,000) in children aged <5 
years; in other places, especially in Asiatic countries such as Korea (105/100.000), Taiwan 
(69.0/100,000), China (55/100,000), and in Hong Kong (39.0/100,000); in New Zealand, 
8.1/100,000) were registered; in the U.S. (17.1/100.000), Canada (26.2/100,000); in Europe,( 
10/100.000) new cases are reported annually, while in Hispanic countries, 11 new cases are 
registered per year, and in Latin America, no exact figures are available, but it as been 
estimated that there are 3.0/100,000 cases (Yahi Lin, 2010 ;Martinez,2003 Nakamura, 2008).    
In Mexico, the first case of KD was communicated by Rodríguez in 1977 (Rodríguez, 1977); 
from that date until June 2010, registries of case series published in medical journals in 
Mexico added up to 155 patients (Sotelo, 2011). 
1.3 Etiology 
The causal agent has not been identified 44 years after the original description; very diverse 
bacterial viral agents, as well as mites, have been considered, in addition to chemical 
substances, without fully convincing evidence; it has been suggested that the disease is 
related with superantigenic toxins due to their having found selective expansion of the 
cellular families T VB2 and VB8; however, this theory remains controversial. In a 
multicenter prospective study, no significant difference was shown in the prevalence of the 
toxin produced in toxin-producing strains in patients with KD and in control patients who 
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manifested fever due to other causes; with respect to this, on the other hand, an alternative 
hypothesis has been supported regarding that the immune response in KD is polyclonal, 
(antigen-driven, i.e., similar to a conventional antigen) rather than polyclonal (as found 
typically in superantigen-driven responses), and that an immunoglobulin A (IgA) plasma 
cell possesses a central role (Burns, 2004; Falcini, 2006; Nagata, 2009; Newburger, 2004). 
In animal models, the properties of superantigenic proteins obtained from intestinal tract 
bacteria in 19 children with KD, have been studied it was observed that these had T-cell VB2 
expansion properties in vitro; these superantigens could be involved in the genesis of this 
disease. During the past decade,  Staphylococcus aureus, the Streptococcus virus for influenza, 
and the morbilivirus of the pramyxovirus family, bunyavirus, were investigated as a 
pathogenic agent for KD  (Burns, 2004; Esper 2005; Falcini, 2006; Nagata, 2009; Rochol, 2004). 
Observations have also acquired importance concerning the participation of adenovirus and 
a new human coronavirus, denominated ”New Haven Coronavirus” (Novel human 
coronavirus Nco-NH), identified in respiratory pathway secretions from a 6-month-old 
nursing  infant with typical KD; in addition, KD was found positive in 8-11-year-old 
children utilizing the reverse polymerase transcriptase technique. Also reported has been 
the mycoplasma infection pneumoniae; in a recent publication, the participation is considered 
of nitric oxide and oxygen reactive species by the neutrophils in acute stages (Bruns, 2004; 
Esper, 2005; Falcini, 2006; Merlin, 2004; Nagata, 2009; Rochol, 2004; Yoshimura, 2009).   
To date, no particular gene has been demonstrated to which the development of KD has 
been attributed; however, the relationship or association has been suggested of a 
polymorphic HLA-E histocompatibility antigen that could participate in the pathogenesis of 
the disease; it also has been considered that an imbalance between the Peroxisome 
proliferator-activated receptor gamma (PPAR-gamma) and low levels of High-molecular-
weight (HMW) adiponectin in the disease can be of clinical importance for future 
development of premature atherosclerosis (Fukunaga, 2010; Lin, 2009). 
2. Pathogenesis 
Explain the disease’s pathogenesis it is complex because of the various interactions among 
increased immunological components, immune system cells, in addition to vascular 
components; currently, it is to difficulty to explain the controversy regarding the imbalance 
the metalloproteins and the tissue inhibitors between KD and other  febrile processes ; 
however, suggested that the complicated pathogenesis of this  illness include this imbalance, 
there have been advances, which we will describe in the following text. (Newburger, 2004, 
Pinna, 2008, Sakata, 2010) 
In the first observations relative to immunological perturbations, we include a marked 
stimulation in the cytokine cascade and in endothelial cell activation, this being the first step 
leading to coronary artery injuries, participating in the activation of CD68 endothelial cells, 
monocytes/macrocytes, and CD8 cytotoxic lymphocytes, and IgA plasma cell appear to be 
involved. The prominence of IgA plasma cells in the respiratory tract, as also occurs in fatal 
virus-associated respiratory infections, has suggested that the respiratory tract can be the 
entrance pathway for causal agents. In the genesis of arterial wall injury, the following 
intervene: Vascular endothelial growth factor (VEGF); Monocyte activator chemotactic 
factor (MACF) or Monocyte chemotactic protein-1 (MCP-1); Tumor necrosis factor-alpha 
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(TNF-α), and diverse interleukins that lead to the development of vasculitis (Neubauer 2004; 
Pinna, 2008,) 
More recently, one study (sakata,2010), showed tahta the circulating  matrix metalloproteins 
MMPs-9 levels are markedly increased in KD, while  MMP-1 and tissue inhibitor 
metalloproteins (TIMPs), showed no significant changes as compared with control groups, 
previous reports demonstrate that MMP 1-2 and TIMP -2 were significantly higher in acute 
stage KD, than controls, those reports showed that the levels of MMPs/TIMPs  were 
increased in other febrile patients, nevertheless there was no significant difference in the 
ratio of MMP/TIMP between febrile and  no febrile patients. This  features could play an 
important role in the vascular remodeling in this disease The expression of   MMP-9 was 
detected in entire myocardium of a patient with acute KD, and staining revealed the 
presence of MMP-9 in Endothelial cells (EC), suggesting that the majority of individual 
monocytes, neutrophils, or myocardial cells express MMP-9. In the Sakata et al, the authors 
showed that MMP-9 mRNA expression in Human cells (HUEVECs) treated with plasma 
MMP-1, -2, and TIMP-2 levels were normal for KD. Plasma MMP-9 increased during the 
disease’s acute phase; MMP-9 stained diffusely in coronary arterial lesions and MMP-9 
mRNA levels were higher in HUEVECs treated with plasma in acute and convalescent 
disease phases. Interleukin (IL)-1B, IL-6, and TNF-alpha stimulated MMP-9 expression. The 
authors conclude that ECs are a source of MMP-9 in vascular lesions, and that KD is 
regulated by cytokines IL-1B, IL-6, TNF-alpha, and interferon gamma.  
In a recent study conducted to clarify the role of peripheral CD8T cells in KD, researchers 
investigated these cells’ activation, proliferation, and effector function, compared with 
healthy/febrile controls. Patients with KD showed a striking increase in early activator 
markers CD69 CD8T cells and in maturation subsets, but HLA-DR CD8T cells, which 
represent late activation, did not increase. The cell division reflected by Ki67, CD8T 
increased in KD and in febrile controls; however, the effector cells were lower in acute than 
in convalescent KD. The CD8T cells denoting cytolytic activity were lower in KD (Ehara, 
2010; Sakata, 2010). 
3. Arterial injury 
In the evolution of the arterial injury, there is a series of changes that can involve not only 
the coronary arteries, but also other arteries, such as those of the muscles, the mesentery 
arteries, the femoral arteries, the iliac, the renal, the axillary, and the brachial arteries; in the 
different stages of the disease, in the median layer, edema, muscle cell disassociation, and 
subendothelial edema are observed, and later, mononuclear infiltration, internal elastic 
lamina destruction, fibroblastic proliferation, metalloprotein matrix-related remodeling, 
active inflammation, fibrous scar, and arterial remodeling or revascularization; the 
progressive stenosis results from the remodeling and the neoangiogenesis ; the intimal is 
markedly thickened and consists of linearly arranged micro vessels, an layer that is rich in 
smooth muscle cells, an fibrous layers many factors are expressed in aneuriysms. (Lau, 2008; 
Sakata, Newburger,2004; 2010; Tai-Lin, 2008) 
4. Myocarditis 
From 1978, it was communicated that myocarditis can present during the acute phase of KD 
and that it can be transitory; 20 years later, it was affirmed that up to 50% of patients with 
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KD can present myocarditis (Fujiwara, 1978; Rowley, 1998). The mechanism of injury is not 
yet clear, whether it is considered as secondary to the action of several cytokines, TNF, 
Interferon, or Interleukins 1 and 6, which can contribute to myocyte contractility 
dysfunction 
On the other hand, there is evidence of myocarditis identified by serialized biopsies of 
myocardia in patients without coronary aneurysms (Takahashi, 1989; Yutani, 1981; 
Yonesaka, 1992). Findings from the histological viewpoint have been diverse, and among 
these are found the following: hypertrophy; myocyte degeneration; fibrosis; infiltration of 
lymphocytes and plasma cells, and disarray of myocardial fibers and, in adults after KD, we 
find the description of kariomyocyte dropout and diffuse fibrosis not in the watershed 
distribution of the epicardial coronary arteries; it has been supposed that the fibrosis is due 
to ischemic damage because of microinfarcts or kariomyocyte inflammatory damage. 
Mycocarditis in KD is characterized by inflammatory cell infiltration from the coronary 
arteries to the myocardiac instersticium, and necrosis of the myocardium is infrequently 
observed (Yoshikawa, 2006); on the other hand, diffuse myocarditis followed by myocardial 
fibrosis can lead to diastolic dysfunction, and in the acute phase of KD, measurement of 
ventricular flow has revealed an abnormal relaxation and has been associated with 
increased levels of type B naturiuretic peptide. 
By other hand Myocarditis  is recognized as a component on the half of KD patients, 
thought the left ventricular dysfunction ;  Ajami,  et al, evaluated  myocardial function in 
patient during acute phase of illnees using the myocardial performance index also known as 
a Tei  index, and they assessed the Tei index, the ejection fraction, shortening fraction and 
valvular regurgitation, pericardial effusion or coronary arterial involvement, they compared 
the changes in acute phase compared with pos-treatment data, confirming left ventricular 
dysfunction these index measures combined systolic and diastolic function is a simple 
sensitive and accurate tool for estimating myocardial function (Ajami 2010;Kurotobi, 2005). 
The pathogenesis of these myocardiac injuries and their consequences in the long term with 
respect to the heart are little understood to date and should not be underestimated; thus, it 
is necessary to establish methodological follow-up patterns in these patients. The possibility 
has also been set forth of reclassifying the clinical signs and other findings regarding left 
ventricle dysfunction in KD (Gordon, 2009; Dahdah, 2009). 
5. Valvulitis 
During the acute phase of KD, approximately 2% of children develop valvulitis followed by 
scarring of the valves leaflets, most commonly in the mitral valve, leading to valvular 
incompetence and the need for valve replacement in a subset of patients (Gordon, 2009; 
Pinna,2008; Sotelo, 2011).  
6. Myocardial infarct  
This is the main cause of death and occurs in 1.4 to 2.8% of patients; this can be caused by 
thrombosis or rupture of aneurisms, which lead to acute infarct; histopathologically, 
changes are observed in the cytoplasm, loss of transversal striae and of the nuclear 
membrane, neutrophil, lymphocyte, and macrophage infiltrate in the dead cell zone, with a 
formation of collagen that will confer later scarring (Schoen and Mitchell, 2008; Newbauer, 
2004; Shimizu, 2009 ) 
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7. Other manifestations 
In the heart, the development of progressive dilation of the aortic root with aortic valvular 
regurgitation has been observed.  Pericardial effusion with ventricular dysfunction has also 
been observed (MacMorrow, 2001). 
8. Ages at presentation 
KD is more frequent in children <5 years of age in 76% of the cases, observing a maximum 
peak at between 2 and 5 years;  in infants <1 year of age, special characteristics are present, 
with a higher number of atypical cases and also more complications. In adolescents, it 
presents with a lesser frequency; recently, a series of cases has been described in adult 
patients that, until now, has been limited to one hundred cases, in the majority of which the 
disease appears, to a greater degree, follow an atypical course, such as has been described in 
children, the existence of Incomplete KD in adults, suggest that the study algorithm 
proposed by multidisciplinary committee on experts to diagnose  of this disease in  children 
could be useful in adults . On the other hand, in patients with HIV, it is more feasible to find 
patients affected with KD in adults (Gommar-Menesson, 2010; Seve, 2011). 
The children at greatest risk of complications and of having a deficient treatment response 
are those aged <1 year. With respect to gender, masculine predominates at a ratio of 1.7:1 
(Cimaz, 2009; Newburger, 2004). 
8.1 Season of the year 
KD can present in isolated fashion, but in areas of greatest prevalence, epidemic outbreaks 
are registered, and it is the months of spring and fall that have the greatest number of cases, 
coinciding with the times of greatest incidence of viral diseases (Lin, 2010; Newburger, 
2004). 
9. Clinical manifestations 
Currently, the most important elements for diagnosis are based on the clinical findings; 
included among these are fever >4 day, at the age < 5 years, associated with skin rash, 
oropharyngeal and lip erythema conjunctival injection, edema of the hands and feet, 
erythema of palms and soles, and, in the convalescent phase, these signs comprise the 
principal criteria for being able to make a diagnosis of KD of day 4 of the illness 
(Newburger, 2004). Periungual desquamation is a sign that presents at between 10 and 21 
days of disease evolution, although additional clinical signs can also be observed, such as 
hepatomegaly, ictericia, abdominal pain, vesicular colic pain (gall bladder), vomiting, 
diarrhea, dysuria, the arthralgias, and interphalangeal articular pain; other less frequent 
clinical data have been described, but it is urgent to have among these the deep, transverse 
grooves across the nail (Beau’s lines). These changes appear 1 or 2 months after disease 
initiation; striated leukonychia, which consists generally of two smooth bands that are 
parallel to the lunula of the nails, apparently are associated with Periungual edema and can 
be observed ca. day 9 of disease evolution (Berard, 2008; Imaz, 2009; Yeo, 2009). 
Another sign observed in children <1 years of age is reddening of the Bacillus Calmette-
Guérlin (BCG) scar, which is considered to be related with a cross-reaction (Shina, 2005) of 
the thermal shock protein HPS 65 and its human homologue, HPS; on the other hand, the 
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hydrotropic biliary vesicle, colonic edema, and pulmonary nodules are rare manifestations, 
but should be considered when there is abdominal pain in acute- state and persistent 
respiratory manifestations (Freeman, 2003; Kim, 2008; Newbauer, 2004; Rigante, 2010)  
(Table 1).  
In cases of suspicion of KD that are catalogued as atypical, we should bear in mind the 
following data that are useful in the diagnosis: fever for >9 days; skin exanthema for some 
time, and the three basic disease signs, including leukocytosis with neutrophilia, elevation 
of transaminases, and albumin <3.5 g/dl, and thrombocytosis. There is also a scoring 
system, designed by Harada, for predicting coronary aneurisms, comprising the following 
parameters: masculine gender; age <1 year; leukocytes >12,000 × mm3; reactive C protein >3 
mg/dl; hematocrit >35; platelets >350, 000  mm3,  and albumin >3.5 g; a patient is 
considered to be at risk if he/she scores 4 or more points between day 1 and day 9.  
There are serious difficulties involved in establishing the diagnosis in breast-feeding infants 
and in children aged <1 year, because the patients do not express the characteristic pain; it 
is, therefore, important to possess laboratory support in determining creatine kinase with 
the MB fraction, in addition to the Electrocardiogram (EKG) to observe test segment, Vf, Q, 
and T waves, echocardiogram, and myocardial perfusion and magnetic resonance 
gammagrams (Bao-thing, 2010; Javadzagean, 2009; Newburger, 2004; Shulman, 2003). 
 
Basic signs 
Persistent fever for >5 days  
The presence of four or more signs of the disease  
Conjunctival bulbar injection without exudates  
Changes in lips and oral cavity  
Erythema, cracking of lips, strawberry tongue, diffuse oral injection, and pharyngeal 
mucosa 
Erythema of palms, soles, edema of hands, feet, leukonychia striata in nails at day 9 
Polymorphous exanthema 
Cervical lymphoadenopathy (>1.5 cm in diameter), unilateral or bilateral 
Periungual peeling of fingers, toes, in weeks 2 and 3, transversal grooves in fingernails 
(Beau’s lines) in week 4. 
_______________________________________________________________________ 
Other Clinical Features 
Cardiovascular System: Precordial murmur, congestive heart failure, myocarditis, 
pericarditis, pericardial effusion, valvular regurgitation, coronary artery abnormalities. 
Aneurysms of medium-size non coronary arteries. 
Skin: Raynaud’s phenomenon, peripheral gangrene, desquamating rash in groin, 
erythema, induration at Bacillus Calmette-Guérin (BCG) inoculation site. 
Musculoskeletal System: Arthralgias, arthritis. 
Gastrointestinal Tract: Diarrhea, vomiting, abdominal pain, hepatic dysfunction, hydops 
of gallbladder, colonic edema. 
Central Nervous System: Irritability, sensorineural hearing loss, aseptic meningitis. 
Genitourinary system: Meatitis, uretritis. 
________________________________________________________________________ 
(Berard, 2008; Kim, 2008; Newburger, 2004; Shina, 2005; Sotelo, 2011). 
Table 1. Basic signs and other findings that can present in Kawasaki disease. 
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10. Laboratory tests and others 
There are no specific laboratory studies, although leukocytosis, an increase in globular 
sedimentation speed, and a discrete elevation of bilirubins in 10% of patients tend to be 
observed during the first 2weeks, as well as a moderate increase of transaminases in 40% of 
cases; in the general urine test, elevated leukocytes can be observed in 4 to 6 of every 10 
patients, and thrombosis with a 3- to 6-week duration. In addition, with positive C-reactive 
protein in concentrations >6 mg/l, other studies have been recommended that suggest 
vasculitis, such as the following: Antinuclear antibodies (ANA); Anti-neutrophil 
cytoplasmic antibodies (ANCA), and endothelial anti-cellular antibodies, which have not 
demonstrated full usefulness and that can lead to confusion; in determination of Creatinine 
phospho kinase (CPK), MB fractions are useful for patients with very severe clinical pictures 
and with risk points that suggest greater susceptibility for presenting myocardial infarct. 
Methods have also been developed, such as determination of tryptophase and kynurenine 
in plasma by the liquid chromatography method, finding higher levels in patients with KD; 
this is a method that, once validated, could have an application as a useful laboratory 
diagnostic index; also, in patients with atypical clinical situations, it has been suggested that 
determination of natiuretic peptides is a good marker of evolution to myocardial infarct, 
and it has been recommended that this could be added to the diagnostic tests (Card, 2009;  
Dahdah, 2009; Kurotobi, 2005; Javadzagean, 2009; Newburger, 2004; Shulman, 2003; Zhan, 
2009). 
It has been found recently that early neutropenia indicates that circulating neutrophils on 
day 10 of illness evolution can play an important role in following the sequence of the 
formation of coronary artery injuries (Onouchi, 2009). 
More recently, the measurement has been proposed of CD69 CD8T in peripheral blood as a 
marker to determine disease progression, treatment response, and convalescence in KD 
(Ehara, 2010). 
On the other hand, studies have been conducted in order to identify whether there are 
genetic markers related with risks of complications in children with KD, and 
polymorphisms found in the HLA-E gene have been associated with the possibility of the 
development of coronary aneurysms; on the other hand, alterations in the extracellular 
matrix associated with Pro-collagen type III (PIIINP) and metalloproteins identified with 
biomarkers in 35 adolescents and young adults who had KD have shown an association 
between high levels of PIIINP and the severity of the coronary injuries; nonetheless, more 
confirmatory studies are required in this respect (Lin MT, 2008; Lin YJ, 2009). Unfortunately, 
many of these procedures are not within the reach of the poorest countries (Sotelo, 2007, 
2011). 
10.1 Thoracic x-rays 
These can show pneumonic infiltrate in 15% of cases, especially in patients who present 
cough and respiratory difficulty, although there are radiologic changes that can be caused 
by pneumonitis, hemorrhages, and vasculitis-related pulmonary nodules (Freeman, 2003). 
10.2 Electrocardiogram (EKG)  
EKG can be normal in the first disease phases, or can show changes such as tachycardia, PR-
QT prolongation, and abnormal Q waves (data of the infarct). 
www.intechopen.com
 
Advances in the Etiology, Pathogenesis and Pathology of Vasculitis 430 
10.3 Echocardiography 
This is a study conducted in the physician’s office that is perhaps the most important in the 
diagnosis and it is necessary in the acute phase and within the first 15 days, independently of 
adequate treatment, and is especially required in children with an atypical or incomplete 
clinical situation who manifest fever and at least four basic disease signs. This procedure is 
also necessary to demonstrate left ventricular function in patients with myocarditis and 
shortening of the fraction of the left ventricle with (<0.28)-decreased values; however, fraction 
shortening increased significantly after treatment; also is utilized Tei  index for measures 
combined systolic and diastolic function and estimating  myocardial disfunction  as an 
evidence of myocarditis, these has  been demonstrated by means of other methods, for 
example, utilizing Galio citrate and scanner (planar or single-photon-emission [SPE]-CT) and 
Tc labeled with blood cell scans. By these methods and by echocardiography, it has been 
observed that there is improvement in the myocarditis after treatment. This situation probably 
is related with the fact that myocarditis has been considered as a transitory event, without its 
being studied more profoundly (MacMorrow, 2001; Newburger, 2004; Yoshikawa, 2006). 
10.4 Perfusion gammagrams 
To demonstrate coronary injuries,  there are procedures that are also utilized that permit 
greater precision in the identification of these coronary lesions; among these procedures are 
found myocardial perfusion gammagrams and coronariographies; it is also possible to 
request coronary Angiography by magnetic resonance (MRA), which provides images 
equivalent to those of coronary angiography. In addition, there as also been information on 
flow in dilated arteries. Another procedure such as Electron beam computed tomography 
(EBT) is employed to estimate the characteristics of the myocardium and is useful for 
detecting progressive myocardial ischemia. Spiral CT (Multislice Spiral Computed 
Tomography) EBT is a non-invasive resource that is comparable with coronary angiography 
for visualizing arterial stenosis in children with KD; lately, there has been a 
recommendation for the use of Dual CT (DSCT) as a resource of greater usefulness than the 
color Doppler echocardiogram for the detection of coronary abnormalities. Notwithstanding 
this, of recent date technological innovations in echocardiography have also been described 
that allow to evaluate treatment response to GGIV, assessing the cardiac walls. Some of 
these procedures could in the future constitute the diagnostic and follow-up standards in 
KD (Abe, 2010; Bao-Ting, 2010; Endoh, 2004; Magroverni, 2004).    
11. Treatment 
Early identification of this disease and initiating treatment with gammaglobulin and aspirin 
during the course of week 1 has demonstrated that this avoids the development of coronary 
injuries and diverse cardiovascular injuries that, in the acute as well as in later disease 
stages, place the patient’s life at risk (Mueller, 2009; Newbauer, 2004).   
The most utilized treatment is the application of Intravenous gammaglobulin (GGIV) at a 
dose of 2 per kg in a sole dose for a 12- infusion; this is the most accepted treatment and has 
allowed to the reduction of prevalence of aneurysms to <5% and a mortality of 2% to 0.3%, 
although the GGIV scheme is at a dosage of 400 mg × kg × day for 5 days, plus aspirin at 80 
to 100 mg × kg × day. According to response, the GGIV dose can be repeated, or corticoids 
can be added, especially in refractory cases (Cha, 2008; Chung, 2009; Falcini, 2006; Hung, 
2009; Miura, 2008; Newbauer, 2004;  Ogata, 2009; Okada, 2009; Sano, 2010; Tremoulet, 2008). 
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Other therapeutic agents have been recommended, such as cyclophosphamide, 
cyclosporine, and Ulinastatin in a limited number of cases (Newbauer, 2004). 
Infliximab is a product based on monoclonal antibodies against Tumor necrosis factor-alpha 
(TNF-α), and it has been employed successfully in cases of resistance to gammaglobulin. 
(Burns,2008) 
Abciximab is another monoclonal antibody that inhibits the platelet glycoprotein receptor 
IIb/IIIa, favoring the more rapid resolution of the aneurysms; however, these drugs require 
greater clinical experience (Burns, 2008; Williams, 2002; Tremoulet, 2008).  
Concerning recommendation for treatment of KD during the past 3 years, it as been 
mentioned that the greatest effectiveness in cases of relapse or resistance is obtained on 
utilizing pulses of methylprednisolone in addition to GG. 
In cases of recurrence of fever or resistance to GGIV, this combination has even been 
recommended as initial therapy (Cha, 2008; Chung, 2009; Miura, 2008; Ogata, 2009; Okada, 
2009; Sha, 2008).                  
Cardiovascular sequelae of KD in the adult in Japan. A systematical follow-up all the 
patients who were diagnosed with this disease with observation periods of >15 years; The 
Committee of Experts of the American Heart Association has designed a follow-up model 
that includes stratification in five levels (I toV),Table 2 (Newburger,2004), the latter 
including coronary changes, size of the aneurysms, and the obstruction, and they also 
provided pharmacological recommendations and the procedures and diagnostic studies, 
both invasive and non-invasive, that should be performed, in addition to the surgical 
options (Gordon, 2009; Newburger, 2004). Included  an indication that there should be long-
term follow-up for patients who had echocardiogram-indicated coronary ectasias in an 
acute episode and who presented  for development of aneurysms, independently of the 
internal diameters of these, but with special emphasis on patients who presented giant 
aneurysms of >8 mm, and also subjects who additionally had other cardiovascular risk 
factors, such as obesity and hypertriglyceridemia. 
The complications most frequently observed in adults as sequelae of KD are the following: 
angor pectoris; ventricular tachycardia ventricular with left cardiac failure, secondary to 
calcified aneurysms, myocardial infarct, arrhythmias, and sudden death (Gordon JB, 2009). 
 
Risk Level I—Patients with no coronary artery changes on echocardiography at any stage of the 
illness  
No antiplatelet therapy is needed beyond the initial 6 to 8 weeks after the onset of illness.  
No restriction of physical activity is necessary after 6 to 8 weeks.  
Because the degree of future risk for ischemic heart disease in this category of patients is 
still undetermined, periodic assessment and counseling about known cardiovascular risk 
factors every 5 years is suggested.  
Coronary angiography is not recommended.  
Risk Level II—Patients with transient coronary artery ectasia or dilatation (disappearing within 
the initial 6 to 8 weeks after the onset of illness)  
No antiplatelet therapy is needed beyond the initial 6 to 8 weeks after the onset of illness.  
No restriction of physical activity is necessary after 6 to 8 weeks.  
Risk assessment and counseling is recommended at 3- to 5-year intervals.  
Coronary angiography is not recommended.  
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Risk Level III—Patients with isolated (solitary) small to medium (>3 mm but <6 mm, orzscore 
between 3 and 7) coronary artery aneurysm in ≥ 1 coronary arteries on echocardiography or 
angiography  
Long-term antiplatelet therapy with aspirin should be administered, at least until the 
aneurysms regress.  
Physical activity without restriction in infants and children in the first decade of life is 
permitted after the initial 6 to 8 weeks. Stress tests with myocardial perfusion evaluation 
may be useful in the second decade to guide recommendations for physical activity. 
Participation in competitive collision or high-impact sports is discouraged in children 
receiving antiplatelet therapy.  
Annual follow-up by a pediatric cardiologist with echocardiogram and ECG is 
recommended. Stress tests with myocardial perfusion imaging is recommended every 2 
years in patients >10 years old.  
Coronary angiography is indicated if myocardial ischemia is demonstrated by stress tests 
with imaging.  
Risk Level IV—Patients with  1 large coronary artery aneurysm ( 6 mm), including giant 
aneurysms, and patients in whom a coronary artery contains multiple (segmented) or 
complex aneurysms without obstruction  
Long-term antiplatelet therapy is recommended. Adjunctive therapy with warfarin with a 
target INR of 2.0:2.5 is recommended for patients with giant aneurysms. Daily 
subcutaneous injections of low-molecular-weight heparin merits consideration as an 
alternative to warfarin for infants and toddlers, in whom blood drawing for INR testing is 
difficult. Low-molecular-weight heparin also may be used as a bridge during the initial 
phase of warfarin therapy or during the reintroduction of warfarin after the interruption of 
therapy for the purpose of elective surgery; therapeutic levels are assessed by measuring 
antifactor Xa levels. Some experts recommend a combination of aspirin and clopidogrel for 
patients with multiple or complex aneurysms.  
Recommendations about physical activity should be guided by annual stress tests with 
myocardial perfusion evaluation. Collision or high-impact sports should be discouraged 
because of the risk of bleeding. Participation in noncontact dynamic or recreational sports is 
encouraged if no evidence exists of stress-induced myocardial ischemia.  
Cardiology evaluation with echocardiogram and ECG should be done at 6-month intervals. 
Stress tests with myocardial perfusion evaluation should be performed annually. The 
patient should be monitored for known risk factors of atherosclerosis and his or her family 
should be counseled accordingly.  
Cardiac catheterization with selective coronary angiography should be performed 6 to 12 
months after recovery from the acute illness, or sooner if clinically indicated, to delineate 
the complex coronary artery anatomy. Follow-up angiography may be indicated if 
noninvasive studies suggest myocardial ischemia. In addition, elective cardiac 
catheterization in the absence of noninvasive evidence of myocardial ischemia may be 
useful to rule out subclinical major coronary artery obstructions in some situations, such as 
when the patient experiences atypical chest pain, the ability to perform dynamic stress 
testing is limited by age, unique activity restrictions or insurability recommendations are 
needed, or the anatomy or size of the aneurysm cannot be clearly defined by 
echocardiography for decisions regarding anticoagulation.  
For females of childbearing age, reproductive counseling is strongly recommended.  
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Risk Level V—Patients with coronary artery obstruction confirmed by angiography
Long-term antiplatelet therapy with or without adjunctive therapy with warfarin 
anticoagulation is recommended (see Risk Level IV)  
ß-Adrenergic–blocking drugs should be considered to reduce myocardial oxygen 
consumption.  
Recommendations about dynamic physical activities should be based on the patient’s 
response to stress testing. Collision or high-impact sports should be discouraged because of 
the risk of bleeding. Patients should avoid a sedentary lifestyle.  
Cardiology evaluation with an echocardiogram and ECG should be obtained at 6-month 
intervals. Stress tests with myocardial perfusion evaluation should be performed annually. 
The patient should be monitored for known risk factors of atherosclerosis and his or her 
family should be counseled accordingly. 
Cardiac catheterization with selective coronary angiography is recommended to address 
the therapeutic options of bypass grafting or catheter intervention and to identify the extent 
of collateral perfusion. Repeat cardiac catheterization may be indicated when new onset or 
worsening myocardial ischemia is suggested by noninvasive diagnostic testing or clinical 
presentation. If the patient has undergone surgical revascularization or a catheter 
intervention, then repeat cardiac catheterization may be indicated to evaluate the efficacy of 
the treatment.  
For females of childbearing age, reproductive counseling is strongly recommended.  
Table 2. Risk Stratification according American Heart association (Newburger, 2004). 
12. Conclusion  
In view of the growing number of patients with KD who have been identified in different 
parts of the world, it is necessary for Pediatricians, Pediatric Cardiologists, Pediatric 
Cardiologist Internists, and Cardiologists for adults to carry out correct follow-ups, taking 
into consideration that patients can develop vascular injuries with different types of 
atherosclerosis, coronary aneurysms, with valve incompetence due to scarring of the leaflets 
or progressive aortic root dilation, and it is important not to underestimates the myocardial 
lesions, and the biochemical markers of this inflammatory process during acute phase, 
including moreover. diffuse fibrosis or local scarring in regions of myocardial, ischemia or 
infarct (Takahasi, 1989; Dahdah, 2009). 
KD-associated inflammatory damage can potentially affect all of the components of the 
cardiovascular system and even other bodily areas as a consequence of vasculitis; thus, 
systematic follow-up  is necessary until adult age in all children who have had this disease, 
even when his/her manifestations have not been severe, and especially in these children 
who manifested myocarditis without coronary artery injuries, because to date we do not 
know the characteristics and long-term consequences of this particular problem. On the 
other hand, some reports note an up to 12% frequency for myocarditis. The treatment for 
sequelae in coronary arteries is infrequent in pediatric ages and in the adult, and will 
depend on the damage established and the patient’s evolution at the long term; the decision 
for the choice of the most adequate procedure (intervention with percutaneous catheter or 
surgery for bypass placement or specific procedures for valvular problems) will be 
determined by Cardiologists and Cardiovascular Surgeons (Careaga-Reyna, 2008; Crystal, 
2009; Fukazawa, 2010; Gil-Veloz, 2009; Huerta-García, 2009; Kato, 1996; Mueller, 2009; 
Simizu, 2010; Sudo, 2010; Sotelo, 2011,Vizcaino, 1991). 
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